Chae Joo-yup

I'll research this attorney before drafting.

Let me verify the identity details and the litigation outcomes.

Chae Jooyup (채주엽) — patent litigation profile

Focus areas and side. The tracked record contains a single patent case: Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd. (N.D. W. Va., No. 1:23-cv-00094), an aflibercept/EYLEA biosimilar dispute under the BPCIA in which Samsung Bioepis appears as defendant and Chae appears in an in-house capacity. That single data point — 0 plaintiff-side, 1 defendant-side — is too thin to support a claim of a patent-litigation specialization. Web-searchable practice descriptions frame his work more broadly as life-sciences and healthcare legal practice: biotech/pharma and medical-device transactions, regulatory and antitrust enforcement matters, dispute resolution, and corporate governance, with patent and biosimilar risk management described as one component. Technology focus, to the extent one exists, is pharma/biologics and medical devices rather than software, Wi-Fi/standards, or mechanical arts.

Firm context. Chae is currently in-house at Samsung Bioepis, which he joined in December 2025 as vice president and head of the legal team, per Seoul Economic Daily and Bloter. Before that he was a partner at Yulchon LLC (Seoul), where he led the firm's medtech & bio team and was named in Asia Business Law Journal's Korea's Top 100 Lawyers 2025. Prior in-house roles: vice president, general counsel and board secretary at SK Biopharmaceuticals; general counsel of its U.S. subsidiary SK Life Science, Inc.; internal audit vice president at the SK SUPEX Council; and legal director, North Asia at Johnson & Johnson MedTech / J&J Korea. He began his career as legal counsel at LG Electronics and GS Caltex. (One aggregated résumé-scraping profile lists the Yulchon partnership as starting in 2018, which conflicts with his SK tenure through 2023; the 2023 start date is better sourced.)

Notable matters and PTAB. Search results did not yield a verifiable reported trial outcome, verdict, or Federal Circuit disposition in the tracked Regeneron v. Samsung Bioepis case, and no PTAB filings name him as counsel — the IPR papers in that patent family (e.g., IPR2023-00739 on U.S. 10,888,601; IPR2025-00176 on U.S. 11,084,865) list Quinn Emanuel attorneys as Samsung Bioepis's counsel of record, which is typical for in-house participants. Several matters described in his Yulchon and law.asia biographies involve Korea Fair Trade Commission and Korea Customs Service enforcement rather than U.S. patent litigation. This profile should therefore be read as a Korean in-house healthcare/pharma legal executive with biosimilar-patent exposure, not as a U.S. patent litigator with a track record of reported results. Name-collision caution: a "Mr. Chae" appearing in Spigen Korea v. Ultraproof (C.D. Cal. 2018) as prosecuting/litigation counsel, and the "Chae" prior-art reference in a Yangtze Memory v. Micron IPR, are different individuals.

Bar/education. Korean bar (passed the 43rd National Judicial Examination, 2001) and admitted in New York (2011); LL.B., Seoul National University College of Law; LL.M., Georgetown University Law Center.